Medication Study for the Symptoms of Systemic Lupus Erythematosus (SLE)

Other
Infectious Disease
Official Title A PILOT, PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Purpose

The purpose of this study is to test the effects of a new drug called CC-22. Researchers want to find out if it does or does not improve the symptoms of those diagnosed with Systemic Lupus Erythematosus (SLE).

Could this study be right for you?

You may be eligible for this study if:

  • You have been diagnosed with SLE
  • You have had SLE longer than (or equal to) six (6) months
  • You have three (3) or more tender joints at the baseline visit
  • You have skin manifestations of Lupus

Age Range

18 and up